Immunoglobulin-mediated membranoproliferative glomerulonephritis
MONDO:0014005Glomerulonephritis characterized by mesangial proliferation, endocapillary proliferation, and glomerular capillary wall remodeling with immune complex deposits from classical complement pathway activation.
Also known as: Ig-mediated MPGN, Ig-mediated membranoproliferative glomerulonephritis, NPHS7, immune complex mediated membranoproliferative glomerulonephritis, immunoglobulin-mediated MPGN, immunoglobulin-mediated membranoproliferative glomerulonephritis, membranoproliferative glomerulonephritis type I, mesangiocapillary glomerulonephritis type 1
19 clinical trials for this condition and its sub-types, 12 tagged with Immunoglobulin-mediated membranoproliferative glomerulonephritis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Can a targeted therapy tame rare kidney diseases in daily practice?
Disease control Recruiting nowThis study looks at how well the medication pegcetacoplan works and how safe it is for people with two rare kidney conditions: C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). Researchers will follow about 150 patients who are…
Phase 4 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug combo aims to tame rare kidney diseases
Disease control Recruiting nowThis Phase 2 study tests a new drug called ADX-038, alone or with another drug (telitacicept), in 30 Chinese adults with kidney diseases caused by an overactive complement system (IgA nephropathy, C3G, or IC-MPGN). The goal is to see if the treatment is safe and can help control …
Phase 2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New siRNA drug aims to tame kidney disease
Disease control Recruiting nowThis Phase 2 study is testing a new drug called ADX-038 in 45 adults with complement-mediated kidney diseases, such as IgA nephropathy and C3G. The drug is an siRNA that targets the complement system, which is overactive in these conditions. Researchers are checking if it is safe…
Phase 2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for rare kidney patients: Long-Term drug trial shows promise
Disease control Recruiting nowThis study looks at the long-term safety and effectiveness of a drug called iptacopan for people with two rare kidney diseases: C3 glomerulopathy and IC-MPGN. About 225 adults who have already completed a previous iptacopan study will take the drug for an extended period. The goa…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New hope for rare kidney disease: iptacopan trial aims to protect kidneys
Disease control Recruiting nowThis study tests a drug called iptacopan in people with a rare kidney disease (IC-MPGN). About 106 adults and teens will receive either iptacopan or a placebo. The main goal is to see if iptacopan reduces protein in the urine and helps preserve kidney function over 18 months.
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC